YGION Biomedical Awarded Grant from the Austrian Research Promotion Agency to develop Individualized Cancer Immunotherapies

2024-06-22T13:15:54+02:00June 18, 2024|News|

YGION Biomedical GmbH, a company dedicated to developing individualized neoantigen-based cancer immunotherapies, today announces further fundraising news with the award of a significant Life Sciences grant from the Austrian Research Promotion Agency (Forschungsförderungsgesellschaft; FFG). This non-dilutive funding will be used over the next 12 months to further development YGION’s unique YGNITE™ technology platform and support preclinical development of YGION’s lead program, YG1. YGION is committed to developing individualized “plug-and-play” cancer vaccines using a proprietary suite of technologies to identify, produce and target the delivery of relevant peptide neoantigens resulting in safe, exceptionally potent, and precise targeted activation of the patient’s immune system. “With this support from the FFG, we will take an important step forward … read more